Grant: Project Grant
Ottawa Hospital Research Institute
$1,047,500.00
Overcoming barriers to effective cancer immunotherapy with an engineered virus based therapeutic
EF 2023-24
Résumé
The development of strategies to awaken a patient's immune system to recognize and attack their own tumour has revolutionized cancer therapy. We are developing virus based therapeutics designed to infect and selectively spread in tumours and leave normal tissues uninfected. These viruses can be programmed to locally produce therapeutic proteins within the tumour acting as "mobile pharmacies" that dispense medicines where and when they are needed. We have added in a new technology that allows us to remotely control the replication of the virus using FDA approved drugs. Our long term goal is to create a new suite of therapeutic viruses armed with multiple weapons to attack and kill tumour cells.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
495807
Name
Bell John C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Overcoming barriers to effective cancer immunotherapy with an engineered virus based therapeutic
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$1,047,500
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Cancer; Engineering; Extracellular Matrix; Immune Activation; Immune Evasion; Inducible Promoters; Oncolytic Virus; T Cell Engager; T Cells
Abstract
The development of strategies to awaken a patient's immune system to recognize and attack their own tumour has revolutionized cancer therapy. We are developing virus based therapeutics designed to infect and selectively spread in tumours and leave normal tissues uninfected. These viruses can be programmed to locally produce therapeutic proteins within the tumour acting as "mobile pharmacies" that dispense medicines where and when they are needed. We have added in a new technology that allows us to remotely control the replication of the virus using FDA approved drugs. Our long term goal is to create a new suite of therapeutic viruses armed with multiple weapons to attack and kill tumour cells.
Competitiondate
202305
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Bell, John C
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,047,500~ $0~
